Study: Mesothelioma Patients with CD70 Protein Have Worse Prognosis
An international team of pathologists has identified a new protein often found on pleural mesothelioma tumor cells.
The discovery could lead to a more accurate prognosis for patients and future treatment advances.
Researchers found for the first time that mesothelioma patients expressing higher levels of the CD70 protein typically experience a much shorter survival, regardless of cell type or treatment type.
“These markers might be useful for MPM [malignant pleural mesothelioma] prognostic evaluations, as well as targeted therapeutics,” the study authors wrote. “Further analyses in syngeneic mouse models demonstrate...
Source: Asbestos and Mesothelioma News - December 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart
(City of Hope) Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the FDA, reports a City of Hope-led study. Published in The Lancet Oncology, the study is the first to show the benefit of tivozanib for patients with renal cell carcinoma (kidney cancer) who had received two or more previous therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2019 Category: Cancer & Oncology Source Type: news
Renal Cancer Research by Sengenics and the University of Leeds Awarded...
This collaboration will focus on discovery of novel biomarkers for renal cell carcinoma (RCC), with the goal of developing an autoantibody-based early diagnostic test for this disease(PRWeb November 26, 2019)Read the full story at https://www.prweb.com/releases/renal_cancer_research_by_sengenics_and_the_university_of_leeds_awarded_early_detection_primer_grant_funding_from_cancer_research_uk/prweb16740467.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 26, 2019 Category: Pharmaceuticals Source Type: news
Lenvatinib, Pembrolizumab Combo Shows Promising Results in Metastatic RCC
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - November 5, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news
AVEO Oncology Announces Regulatory Update For Tivozanib In Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2019-- AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 4, 2019 Category: Drugs & Pharmacology Source Type: news
Renal Cell Carcinoma: 5 Things to Know Renal Cell Carcinoma: 5 Things to Know
What you need to know about the latest data on treating this common cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news
Pediatric Renal Cell Carcinoma Pediatric Renal Cell Carcinoma
What knowledge have we gained regarding the presentation and management of renal cell carcinoma in young patients?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: Urology Journal Article Source Type: news
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
Inactivation of the VHL tumor suppressor gene is the signature initiating event in clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, and causes the accumulation of hypoxia-inducible factor 2α (HIF-2α). HIF-2α inhibitors are effective in some ccRCC cases, but both de novo and acquired resistance have been observed in the laboratory and in the clinic. Here, we identified synthetic lethality between decreased activity of cyclin-dependent kinases 4 and 6 (CDK4/6) and VHL inactivation in two species (human and Drosophila) and across diverse human ccRCC cell lines in culture and xe...
Source: Signal Transduction Knowledge Environment - September 30, 2019 Category: Science Authors: Nicholson, H. E., Tariq, Z., Housden, B. E., Jennings, R. B., Stransky, L. A., Perrimon, N., Signoretti, S., Kaelin, W. G. Tags: STKE Research Articles Source Type: news
Assessing costs of sunitinib treatment in renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 30, 2019 Category: Drugs & Pharmacology Source Type: news
The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news
Aveo CEO says new data eases concerns about troubled kidney cancer drug
Cambridge drugmaker Aveo Oncology is trying again with its kidney cancer drug tivozanib, disclosing new late-stage data Tuesday that sent its stock price shooting up more than 40 percent and adding $60 million to the troubled company ’s market cap.
Tivozanib was developed to treat advanced renal cell carcinoma, the most common form of kidney cancer. But Aveo has been keeping tivozanib on life support since the FDA rejected it back in 2013 due to a higher risk of death or toxicity than the industry’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 10, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news
Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer
Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 3, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
A Lesson in Screening For Hereditary Kidney Cancer Syndromes A Lesson in Screening For Hereditary Kidney Cancer Syndromes
This case of a renal cell carcinoma in a 30-year-old highlights the need for screening for hereditary kidney cancer syndromes in patients diagnosed with RCC at a young age.Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2019 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news
Setbacks and Advances in Renal Cell Carcinoma Treatment Setbacks and Advances in Renal Cell Carcinoma Treatment
Although we have more evidence against tyrosine kinase inhibitors in the adjuvant setting, studies on immunotherapy and surveillance point toward progress.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
